HE4 as a Relapse Biomarker in Ovarian Cancers

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Ovarian Carcinoma
Interventions
OTHER

Experimental arm

"Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy"

Trial Locations (7)

57085

LONGO Raphaelle, Metz

67065

DEMARCHI Martin, Strasbourg

21 079

BENGRINE-LEVEVRE Leïla, Dijon

67 091

KURTZ Jean-Emmanuel, Strasbourg

25 030

KALBACHER Elsa, Besançon

54 519

GAVOILLE Céline, Vandœuvre-lès-Nancy

51 056

SAVOYE Aude-Marie, Reims

All Listed Sponsors
lead

Institut de Cancérologie de Lorraine

OTHER

NCT02595281 - HE4 as a Relapse Biomarker in Ovarian Cancers | Biotech Hunter | Biotech Hunter